Atria Investments Inc Sells 957 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Atria Investments Inc reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,277 shares of the medical equipment provider’s stock after selling 957 shares during the period. Atria Investments Inc’s holdings in Intuitive Surgical were worth $18,413,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. NewSquare Capital LLC boosted its holdings in Intuitive Surgical by 23.0% in the fourth quarter. NewSquare Capital LLC now owns 123 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 23 shares in the last quarter. J.Safra Asset Management Corp lifted its holdings in shares of Intuitive Surgical by 151.5% in the 4th quarter. J.Safra Asset Management Corp now owns 503 shares of the medical equipment provider’s stock worth $265,000 after purchasing an additional 303 shares in the last quarter. Cookson Peirce & Co. Inc. grew its position in Intuitive Surgical by 0.8% in the 4th quarter. Cookson Peirce & Co. Inc. now owns 5,285 shares of the medical equipment provider’s stock valued at $2,759,000 after purchasing an additional 42 shares during the period. Triad Wealth Partners LLC bought a new stake in Intuitive Surgical during the 4th quarter valued at $244,000. Finally, Exencial Wealth Advisors LLC raised its holdings in Intuitive Surgical by 12.7% during the fourth quarter. Exencial Wealth Advisors LLC now owns 641 shares of the medical equipment provider’s stock worth $335,000 after buying an additional 72 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 1.6 %

Intuitive Surgical stock opened at $557.96 on Wednesday. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The firm has a market capitalization of $198.73 billion, a price-to-earnings ratio of 87.05, a P/E/G ratio of 5.85 and a beta of 1.39. The firm has a 50 day moving average of $571.08 and a 200 day moving average of $530.63.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jamie Samath sold 270 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $540.15, for a total transaction of $145,840.50. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. The trade was a 2.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,598 shares of company stock worth $7,223,467 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and issued a $670.00 target price (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Leerink Partners raised their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Wells Fargo & Company upped their price target on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Bernstein Bank raised their price objective on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Citigroup upped their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.